REG - Futura Medical PLC - Block Listing Application and Total Voting Rights

Futura MedicalAnnouncement

31/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231031:nRSe7514Ra&default-theme=true

RNS Number : 7514R  Futura Medical PLC  31 October 2023

Futura Medical plc

("Futura" or the "Company")

Block Listing Application and Total Voting Rights

 

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products for sexual health and pain relief, announces that,
further to the grant of options announced on 10 October 2023, application has
been made to AIM to extend the Company's existing block listing by 10,590,675
ordinary shares of 0.2 pence each in the Company ("Ordinary Shares").

 

The Ordinary Shares will be issued from time to time pursuant to the Company's
LTIP. Ordinary Shares issued following option exercises and admitted to
trading under the block admission will rank pari passu in all respects with
the existing Ordinary Shares.

 

The increased block listing is expected to become effective on 3 November
2023. The Company will make six-monthly announcements of the utilisation of
the block admission, in line with its obligations under AIM Rule 29.

 

At the time of this announcement, the Company has 300,977,293 ordinary shares
in issue, each carrying one voting right. Since the Company currently holds no
shares in treasury, the total number of voting rights in the Company is
therefore 300,977,293 and this figure may be used by Shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

 

ENDS

 

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

www.Futuramedical.com (http://www.Futuramedical.com)

 

Nominated Adviser and Sole Broker:

Liberum

Phil Walker/Richard Lindley/Benjamin Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Nick Bastin / Jonathan Edwards / Zoe Bolt / Elena Bates

Email: futuramedical@optimumcomms.com (mailto:ziylo@optimumcomms.com)

Tel: +44 (0) 203 882 9621

Notes to editors

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Development and commercialisation
strategies are designed to maximise product differentiation and value creation
whilst minimising risk.

 

MED3000 is Futura's topical gel formulation that is a novel treatment for
erectile dysfunction (ED) through a unique evaporative mode of action. Futura
has conducted two Phase 3 studies using MED3000 in ED; FM57 study which
enabled Futura to be granted a CE Mark in 2021 and FM71 which enabled Futura
to be granted US marketing authorisation. Both studies demonstrated that
MED3000 presents an effective clinically proven treatment for ED with a rapid
speed of onset and a favourable benefit versus risk profile ideally suited for
an 'Over the Counter' classification.

 

Eroxon® is FDA approved in the US, CE marked in Europe and UKCA marked in
the UK as a clinically proven topical treatment for adult men with
erectile dysfunction under the brand Eroxon® with a key claim of "Helps you
get an erection within 10 minutes". Eroxon® is the agreed brand name in
certain regions such as the EU whereas MED3000 continues to be the internal
code name used by the Company and also in reference to countries where
regulatory approval or commercial distribution agreements have not yet been
achieved. www.eroxon.com (http://www.eroxon.com)

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMZMFGKGNGFZM